Literature DB >> 15571477

Pentostatin - pharmacology, immunology, and clinical effects in graft-versus-host disease.

Meghan Higman1, Georgia B Vogelsang, Allen Chen.   

Abstract

Pentostatin (deoxycoformycin), is one of a number of purine analogues. The drug was originally designed to mimic a form of severe combined immune deficiency, characterised by marked T lymphopenia but variable B cell function. Clinically, the drug has been used primarily to treat a rare type of leukaemia - hairy cell leukaemia. Recently, the drug has seen increasing attention as an immunosuppressant. This review will cover the basic pharmacology and immunological effects of pentostatin. The clinical use of this agent in prevention and treatment of graft-versus-host disease will be examined. Although many of these studies are ongoing, this agent has promise as a novel immunosuppressive agent with a new mechanism of action.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15571477     DOI: 10.1517/14656566.5.12.2605

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  2 in total

1.  Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study.

Authors:  Simrit Parmar; Borje S Andersson; Daniel Couriel; Mark F Munsell; Marcelo Fernandez-Vina; Roy B Jones; Elizabeth J Shpall; Uday Popat; Paolo Anderlini; Sergio Giralt; Amin Alousi; Pedro Cano; Doyle Bosque; Chitra Hosing; Leandro de Padua Silva; Michael Westmoreland; J Kyle Wathen; Donald Berry; Richard E Champlin; Marcos J de Lima
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

2.  The adenosine deaminase inhibitor erythro-9-[2-hydroxyl-3-nonyl]-adenine decreases intestinal permeability and protects against experimental sepsis: a prospective, randomised laboratory investigation.

Authors:  Nalan Kayhan; Benjamin Funke; Lars Oliver Conzelmann; Harald Winkler; Stefan Hofer; Jochen Steppan; Heinfried Schmidt; Hubert Bardenheuer; Christian-Friedrich Vahl; Markus A Weigand
Journal:  Crit Care       Date:  2008-10-13       Impact factor: 9.097

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.